Gunkang Pharmaceuticals, Inc

Quick facts

Phase 3 pipeline

• GNS-212-E1 · Diabetes
  GNS-212-E1 is a small molecule that targets the SGLT2 receptor.
• GNS-212-E2 · Diabetes
  GNS-212-E2 is a small molecule that targets the SGLT2 receptor.
• GNS-212-ER · Diabetes
  GNS-212-ER is a small molecule that targets the SGLT2 receptor.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Gunkang Pharmaceuticals, Inc portfolio CI brief
• Gunkang Pharmaceuticals, Inc pipeline updates RSS